Investor Relations

Latest Financial Results

Stock Information

Aurinia Pharmaceuticals Inc.
Nasdaq: AUPH Symbol
Price
Change
Volume
Day Range
52 Wk Range

Company Overview

Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently seeking FDA approval of voclosporin for the potential treatment of LN. Aurinia is actively exploring opportunities to fully realize the untapped potential of novel therapies and create meaningful impact to meet patient needs. The Company’s head office is in Victoria, British Columbia and its U.S. commercial hub is in Rockville, Maryland. The Company focuses its development efforts globally.

view management team  view board of directors

Contact Information

Investor Relations

Glenn Schulman, PharmD, MPH
Senior Vice President, Corporate Communications and Investor Relations
IR@auriniapharma.com

Transfer Agent

Computershare Trust Company of Canada
Shareholder Services Dept.
100 University Avenue
9th Floor
Toronto, ON M5J 2Y1
Canada
T: +1-514-982-7555
service@computershare.com
www.computershare.com